Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages

https://doi.org/10.1016/j.taap.2009.01.024Get rights and content

Abstract

Acrolein is a ubiquitous component of environmental pollutants such as automobile exhaust, cigarette, wood, and coal smoke. It is also a natural constituent of several foods and is generated endogenously during inflammation or oxidation of unsaturated lipids. Because increased inflammation and episodic exposure to acrolein-rich pollutants such as traffic emissions or cigarette smoke have been linked to acute myocardial infarction, we examined the effects of acrolein on matrix metalloproteinases (MMPs), which destabilize atherosclerotic plaques. Our studies show that exposure to acrolein resulted in the secretion of MMP-9 from differentiated THP-1 macrophages. Acrolein-treatment of macrophages also led to an increase in reactive oxygen species (ROS), free intracellular calcium ([Ca2+]i), and xanthine oxidase (XO) activity. ROS production was prevented by allopurinol, but not by rotenone or apocynin and by buffering changes in [Ca2+]I with BAPTA-AM. The increase in MMP production was abolished by pre-treatment with the antioxidants Tiron and N-acetyl cysteine (NAC) or with the xanthine oxidase inhibitors allopurinol or oxypurinol. Finally, MMP activity was significantly stimulated in aortic sections from apoE-null mice containing advanced atherosclerotic lesions after exposure to acrolein ex vivo. These observations suggest that acrolein exposure results in MMP secretion from macrophages via a mechanism that involves an increase in [Ca2+]I, leading to xanthine oxidase activation and an increase in ROS production. ROS-dependent activation of MMPs by acrolein could destabilize atherosclerotic lesions during brief episodes of inflammation or pollutant exposure.

Introduction

Atherosclerotic disease leading to myocardial infarction (MI) and stroke is the leading cause of morbidity and mortality in the Western world (Rosamond et al., 2008). It is currently believed that atherosclerotic lesions develop and grow as a result of vascular inflammation that leads to monocyte infiltration into the vessel wall. Once lodged in the sub-intimal space, the monocytes differentiate into macrophages which take up modified lipoproteins and as a result are transformed into foam cells (Glass and Witztum, 2001, Reiss and Glass, 2006). These processes lead to the formation of distinct lesions (plaque) which are composed of foam cells, a lipid-rich-core and a fibrous, matrix-rich cap. Gradual erosion of this cap or its acute rupture exposes platelets to the underlying matrix proteins and pro-thrombotic molecules, activating them and initiating a thrombotic response. Vascular occlusion at these sites initiates ischemic episodes associated with myocardial and cerebral infarction.

Although physiological events contributing to plaque erosion and rupture are complex, matrix metalloproteinases (MMPs) have been suggested to be play an important role (Galis et al., 1994, Galis et al., 1995, Herman et al., 2001, Sukhova et al., 1999). MMP-mediated degradation of the extracellular matrix (ECM) is vital for several physiological functions including development, morphogenesis, angiogenesis, and tissue repair. Several pathological conditions, such as arthritis, cancer, nephritis, chronic ulcers, and fibrosis (Nagase et al., 2006) are, however, associated with excessive or unregulated MMP activity. MMP dysregulation is also a characteristic feature of cardiovascular abnormalities and increased levels of MMPs have indeed been found in atherosclerotic plaques (Galis et al., 1994, Galis et al., 1995, Halpert et al., 1996, Rajavashisth et al., 1999) and in patients with unstable angina or acute myocardial infarction (Kai et al., 1998, Tziakas et al., 2004).

Acrolein is an aldehydic compound that has been linked in epidemiological studies to cardiovascular pathology (Bhatnagar, 2004, Feron et al., 1991). It is a particularly abundant component of air-borne particulate matter (PM) that arises during the burning of fossil fuels, cigarettes, or other organic material. In addition, acrolein is generated during the cooking or frying of food, is present in the effluent of industrial waste, and exists naturally in vegetables, fruits, and herbs (Feron et al., 1991). Acrolein is also an end product of the metabolism of certain pharmaceuticals (Ludeman, 1999) and can likewise be produced by myeloperoxidase-catalyzed oxidation. It is therefore generated in high amounts at sites of inflammation (Anderson et al., 1997) or lipoprotein oxidation (Anderson et al., 1997, Burke et al., 2001, Feron et al., 1991, Steinberg, 1997), particularly within vascular lesions (Shao et al., 2005). The toxicity of acrolein is a consequence of its strongly reactive, electrophilic, carbonyl group which can react with cellular nucleophiles such as thiols or amines (Esterbauer et al., 1991). Thus acrolein can form adducts with proteins, disrupting cellular signaling or function, or nucleic acids, eliciting mutagenic or carcinogenic effects. In addition, the toxic effects of acrolein can result from indirect means. In particular, chronic acrolein exposure could deplete cellular antioxidants such as glutathione, rendering the cell prone to damage from free radicals. Cardiovascular tissue seems to be particularly sensitive to the toxic effects of acrolein. Epidemiological and animal studies have linked acrolein exposure to arrhythmia (Bhatnagar 1995), hypertension (Feron et al., 1991), atherogenesis (Steinbrecher et al., 1990), dyslipidemia (McCall et al., 1995), and myocardial infarction (Alfredsson et al., 1993, Levine et al., 1984, Stewart et al., 1990). Despite these associations however, the precise mechanisms whereby acrolein contributes to acute cardiovascular pathology is unknown.

Given the extensive evidence implicating oxidative stress in MMP activation (Nelson and Melendez, 2004), we tested the hypothesis that acrolein exposure results in MMP activation and thus contributes to acute plaque rupture and vascular occlusion. Using both a cell culture model and murine atherosclerotic tissue, we did indeed demonstrate that one consequence of acrolein exposure is MMP secretion. Furthermore we show that this was dependent upon increased intracellular calcium and increased ROS generation by xanthine oxidase. Our findings are likely to be of significance in understanding the acute inflammatory responses to acrolein generated endogenously or delivered from the environment.

Section snippets

Reagents and cells

The fluorescent reagents H2DCFDA, fluo-4 AM and DQ-gelatin were purchased from Invitrogen (Carlsbad, CA) while BAPTA-AM and apocynin were from Calbiochem (Gibbstown, NJ). Cell culture media (RPMI 1640) was obtained from Mediatech Inc. (Manassas, VA) and additional media components, fetal calf serum, glutamine, and penicillin/streptomycin were from Clonetics (Allendale, NJ). The MMP-9 antibody, low melting temperature agarose and all other chemicals and reagents were obtained from Sigma (St.

Exposure to acrolein stimulates MMP-9 and ROS in differentiated THP-1 cells

To begin to examine the effect of acrolein on MMPs, we used a macrophage cell line. Macrophages are a major cell component of atherosclerotic lesions (Gerrity, 1981a, Gerrity, 1981b). They express high levels of MMPs that are activated in response to oxidative, pathogenic, and inflammatory stimuli. Hence, we examined whether acrolein also affects MMP production by macrophages. For this, we utilized PMA-differentiated THP-1 cells, a widely used macrophage model. After differentiation in to

Discussion

The major findings of this study are that exposure to acrolein increases intracellular calcium which in turn activates XO in human macrophages. These increases were furthermore associated with an increase in ROS generation and MMP-9 secretion (Fig. 7). Conversely, we found that inhibition of XO prevented ROS generation and decreased MMP-9 secretion from acrolein-treated macrophages. Finally, our experiments with advanced arterial lesions of apoE-null mice showed that treatment with acrolein

Conflict of interest statement

The authors report no conflicts of interest.

Acknowledgments

This work was supported in part by a grant from EPA, NIH grants ES11860, HL55477, HL59378, and a grant from Philip Morris.

References (78)

  • HyvelinJ.M. et al.

    Cellular mechanisms of acrolein-induced alteration in calcium signaling in airway smooth muscle

    Toxicol. Appl. Pharmacol.

    (2000)
  • KaiH. et al.

    Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

    J. Am. Coll. Cardiol.

    (1998)
  • MohantyJ.G. et al.

    A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative

    J. Imm. Meth.

    (1997)
  • NelsonK.K. et al.

    Mitochondrial redox control of matrix metalloproteinases

    Free Radic. Biol. Med.

    (2004)
  • NewbyA.C.

    Metalloproteinases and vulnerable atherosclerotic plaques

    Trends Card. Med.

    (2007)
  • PritsosC.A.

    Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system

    Chem.-Biol. Int.

    (2000)
  • ShaoB. et al.

    Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I

    J. Biol. Chem.

    (2005)
  • SteinbergD.

    Low density lipoprotein oxidation and its pathobiological significance

    J. Biol. Chem.

    (1997)
  • SteinbrecherU.P. et al.

    Role of oxidatively modified LDL in atherosclerosis

    Free Radic. Biol. Med.

    (1990)
  • SwainJ. et al.

    Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material

    FEBS Lett.

    (1995)
  • TakamotoS. et al.

    Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide

    J. Chromatogr. B Anal. Tech. Biomed. Life Sci.

    (2004)
  • TetleyT.D.

    Macrophages and the pathogenesis of COPD

    Chest

    (2002)
  • TritschG.L. et al.

    Modulation of macrophage superoxide release by purine metabolism

    Life Sci.

    (1983)
  • TziakasD.N. et al.

    Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration

    Int. J. Cardiol.

    (2004)
  • AlfredssonL. et al.

    Incidence of myocardial infarction and mortality from specific causes among bus drivers in Sweden

    Int. J. Epidemiol.

    (1993)
  • AndersonM.M. et al.

    Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation

    J. Clin. Invest.

    (1997)
  • BhatnagarA.

    Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes

    Circ. Res.

    (1995)
  • BhatnagarA.

    Cardiovascular pathophysiology of environmental pollutants

    Am. J. Phys. Heart Circ. Physiol.

    (2004)
  • BhatnagarA.

    Environmental cardiology: studying mechanistic links between pollution and heart disease

    Circ. Res.

    (2006)
  • CarmellaS.G. et al.

    Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking

    Chem. Res. Toxicol.

    (2007)
  • ChakrabartiS. et al.

    Regulation of matrix metalloproteinase-9 (MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release

    J. Leuk. Biol.

    (2006)
  • ChakrabortiS. et al.

    Regulation of matrix metalloproteinases: an overview

    Mol. Cell. Biochem.

    (2003)
  • ChoudharyS. et al.

    Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues

    Art. Thromb. Vasc. Biol.

    (2006)
  • DeshmukhH.S. et al.

    Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production

    Am. J. Resp. Cell Mol. Biol.

    (2008)
  • DoehnerW. et al.

    Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies

    Circles

    (2002)
  • DrogeW.

    Free radicals in the physiological control of cell function

    Phys. Rev.

    (2002)
  • EgebladM. et al.

    New functions for the matrix metalloproteinases in cancer progression

    Nat. Rev. Cancer

    (2002)
  • FacchinettiF. et al.

    α,β-unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophages

    Am. J. Respir. Cell Mol. Biol.

    (2007)
  • FarquharsonC.A. et al.

    Allopurinol improves endothelial dysfunction in chronic heart failure

    Circles

    (2002)
  • Cited by (0)

    View full text